Dren Bio, a privately held, clinical-stage biotechnology company developing first-in-class myeloid cell engager therapeutics, announced today that it has entered into a strategic collaboration with ...
We are delighted to partner with a true leader across the region. This agreement is a significant step in our mission to make innovative, high-value therapies accessible to patients globally.” — ...
ORLANDO, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on ...
Introduction Interstitial lung diseases (ILDs) are a heterogeneous group of diseases characterised by varying degrees of inflammation and fibrosis. Among these, fibrotic interstitial lung disease ...
SHANGHAI, Oct. 31, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy ...
SILVER SPRING, Md., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Little Leaves Behavioral Services, a leading provider of center-based Applied Behavior Analysis (ABA) services for preschool-aged autistic ...
The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate ...
SAN FRANCISCO and SUZHOU, China, Oct. 21, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) announced a strategic global collaboration with Takeda (TSE:4502, NYSE:TAK) to advance next-generation ...
Cell and gene therapies (CGTs) are gaining strategic importance across the healthcare landscape, with oncology being the leading therapeutic area followed by cardiovascular and central nervous system ...
Takeda is looking to offload its cell therapy platform and preclinical assets to a yet-unidentified external partner. 137 employees will be let go as part of the move. Takeda will no longer invest in ...
Mechelen, Belgium; October 1, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and its Board of Directors today issued the following statement: On May 13, 2025, Galapagos announced that its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback